Illumina, Inc.(ILMN)
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Latest News & Analysis
Illumina's Strategic Shift: Market Challenges and Opportunities
Illumina (ILMN) faces market challenges, leadership transitions, and evolving competition. This analysis examines board changes, the AGD project, financial performance, and external factors.
Illumina (ILMN) Stock Analysis: Board Restructuring, China Sales Ban, and Growth Opportunities
Illumina (ILMN) faces board changes, a China sales ban, and promising genomic discovery. Dr. Gottlieb's appointment and Meister's addition signal strategic shifts.
Illumina's China Crisis: Strategic Shift and Financial Outlook
Illumina (ILMN) faces China import ban, prompting strategic shifts. Cost cuts, multiomics focus, and global expansion are key. Analysts see long-term value despite near-term challenges.
Illumina's China Crisis: Navigating Import Ban and Cost Cuts
Illumina, Inc. faces headwinds from a China import ban, prompting cost cuts and a search for alternative markets. Despite challenges, the company innovates and focuses on sustainability.
Illumina's China Crisis: Import Ban, Cost Cuts, and the Path Forward
Illumina (ILMN) faces China import ban, triggering cost cuts and a strategic pivot. Focus shifts to multiomics, global markets, and sustainability amid investor concerns.
Illumina Stock Analysis: China Impact, Multiomics Strategy, and Future Outlook
Illumina (ILMN) navigates China import ban, focuses on multiomics, spatial transcriptomics, and ESG initiatives. A deep dive into its market position and outlook.
Illumina (ILMN): Multiomics Expansion, Strategic Roadmap, and Market Analysis
Illumina expands multiomics, partners with Broad Labs, faces financial hurdles. A deep dive into ILMN's strategic roadmap and market analysis.
Illumina's Strategic Roadmap: A Deep Dive into Genomics and Multiomics
Illumina advances in genomics and multiomics, navigating competition and regulatory hurdles while collaborating with Broad Clinical Labs. Key insights for investors.
Illumina (ILMN): Multiomics, Spatial Technologies, and the Future of Genomics
Illumina (ILMN) is strategically shifting towards multiomics and spatial technologies, highlighted by recent collaborations and investor sessions. While analysts see growth potential, financial challenges and competitive pressures remain key considerations.
Illumina's Multiomics Revolution: A Deep Dive into the AGBT Investor Session
Illumina (ILMN) advances multiomics, spatial transcriptomics, and single-cell analysis post-AGBT, collaborating with Broad Clinical Labs to transform genomics.
Illumina: Revolutionizing Genomics with Multiomics and Spatial Transcriptomics
Illumina is revolutionizing genomics with multiomics and spatial transcriptomics. Strategic collaborations and innovation drive growth amidst regulatory challenges.
Illumina Spatial Transcriptomics: Market Impact & Analysis
Illumina unveils novel spatial transcriptomics technology that reshapes genomics with deep financial, regulatory, and market insights.
Illumina Revolutionizes Genomics with New Spatial Transcriptomics Technology
Illumina launches its groundbreaking spatial transcriptomics technology, ushering in a new era for cellular mapping and multiomic analysis.